The process of assessing the decision-making capacity of potential subjects before their inclusion in clinical trials is a legal requirement and a moral obligation, as it is essential for respecting their autonomy. This issue is especially important in psychiatry patients (such as those diagnosed with schizophrenia). The primary purpose of this article was to evaluate the degree of impairment in each dimension of decision-making capacity in schizophrenia patients compared to non-mentally-ill controls, as quantified by the (MacCAT-CR) instrument. Secondary objectives were (1) to see whether enhanced consent forms are associated with a significant increase in decision-making capacity in schizophrenia patients, and (2) if decision-making capacity in schizophrenia subjects is dependent on the age, gender, or the inpatient status of the subjects.
We systematically reviewed the results obtained from three databases: ISI Web of Science, Pubmed, Scopus. Each database was scrutinised using the following keywords: “MacCAT-CR + schizophrenia”, “decision-making capacity + schizophrenia”, and “informed consent + schizophrenia.”
We included 13 studies in the analysis. The effect size between the schizophrenia and the control group was significant, with a difference in means of −4.43 (−5.76; −3.1, p < 0.001) for understanding, −1.17 (−1.49, −0.84, p < 0.001) for appreciation, −1.29 (−1.79, −0.79, p < 0.001) for reasoning, and −0.05 (−0.9, −0.01, p = 0.022) for expressing a choice.
Even if schizophrenia patients have a significantly decreased decision-making capacity compared to non-mentally-ill controls, they should be considered as competent unless very severe changes are identifiable during clinical examination. Enhanced informed consent forms decrease the differences between schizophrenia patients and non-mentally-ill controls (except for the reasoning dimension) and should be used whenever the investigators want to include more ill patients in their clinical trials. Increased age, men gender and an increased percentage of inpatients might increase the differential of decision-making incompetence compared to non-mentally-ill subjects in various dimensions of the decision-making competence as analysed by the MacCAT-CR scale, but the small number of subjects did not allow us (except for one instance) to reach statistical significance.
Hostiuc S. Informed consent [Consimțământul informat]. Cluj-Napoca: Casa Cărții de Știință; 2014.
Beauchamp T, Childress J. Principles of biomedical ethics. Oxford: Oxford University Press; 2005.
Appelbaum PS, Grisso T: MacArthur competence assessment tool for clinical research (MacCAT-CR): professional resource press/professional resource exchange; 2001.
Wang SB, Wang YY, Ungvari GS, Ng CH, Wu RR, Wang J, Xiang YT. The MacArthur Competence Assessment Tools for assessing decision-making capacity in schizophrenia: a meta-analysis. Schizophr Res. 2017;31;183:56–63. making capacity in schizophrenia: a meta-analysis. Schizophr Res. 2016;
Holmes-Rovner M, Wills CE. Improving informed consent: insights from behavioral decision research. Med Care. 2002;40(9):V-30–8.
Sciences CfIOoM. International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics. 2002;182:17.
Hambrecht M, Maurer K, Häfner H. Gender differences in schizophrenia in three cultures. Soc Psychiatry Psychiatr Epidemiol. 1992;27(3):117–21. PubMed
Palmer BW, Dunn LB, Appelbaum PS, Mudaliar S, Thal L, Henry R, Golshan S, Jeste DV. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch Gen Psychiatry. 2005;62(7):726–33. CrossRefPubMed
Cohen BJ, McGarvey EL, Pinkerton RC, Kryzhanivska L. Willingness and competence of depressed and schizophrenic inpatients to consent to research. J Am Acad Psychiatry Law. 2004;32(2):134–43. PubMed
Wang X, Yu X, Tang H, Lan T, Yao G, Si T, Wang H, Li T, Yu L. Reliability and validity of Chinese mandarin version of MacArthur competence assessment tool for clinical research in patients with schizophrenia. Chin J Psychiatry. 2015;48(1):17–22.
- Testing decision-making competency of schizophrenia participants in clinical trials. A meta-analysis and meta-regression
Mugurel Constantin Rusu
- BioMed Central